Systemic Immune Modulation by Stereotactic Radiotherapy in Early-stage Lung Cancer

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2023 Mar 2

PMID 36864234

Authors

Eleni Gkika

Elke Firat

Sonja Adebahr

Erika Graf

Ilinca Popp

Gianluca Radicioni

Simon S Lo

Ursula Nestle

Nils H Nicolay

Gabriele Niedermann

Dan G Duda

Anca-L Grosu

Affiliations

Soon will be listed here.

Abstract

We performed a prospective study of circulating immune cell changes after stereotactic body radiotherapy (SBRT) in 50 early-stage NSCLC patients. We found no significant increase in CD8 cytotoxic T lymphocytes at first follow-up (the primary endpoint) but detected a significant increase in expanding Ki-67CD8 and Ki-67CD4 T-cell fractions in patients treated with 10 Gy or less per fraction. SBRT can induce significant expansion in circulating effector T-cells immediately post-treatment.

Citing Articles

The role of ALBI score in patients treated with stereotactic body radiotherapy for locally advanced primary liver tumors: a pooled analysis of two prospective studies.

Gkika E, Radicioni G, Eichhorst A, Kirste S, Sprave T, Nicolay N Front Oncol. 2024; 14:1427332.

PMID: 39421444 PMC: 11484445. DOI: 10.3389/fonc.2024.1427332.

Immunological signatures from irradiated cancer-associated fibroblasts.

Berzaghi R, Gundersen K, Dille Pedersen B, Utne A, Yang N, Hellevik T Front Immunol. 2024; 15:1433237.

PMID: 39308864 PMC: 11412886. DOI: 10.3389/fimmu.2024.1433237.

Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy.

Murcia-Mejia M, Canela-Capdevila M, Garcia-Pablo R, Jimenez-Franco A, Jimenez-Aguilar J, Badia J Biomolecules. 2024; 14(8).

PMID: 39199286 PMC: 11353221. DOI: 10.3390/biom14080898.

Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.

Zafra J, Onieva J, Oliver J, Garrido-Barros M, Gonzalez-Hernandez A, Martinez-Galvez B Int J Mol Sci. 2024; 25(8).

PMID: 38674117 PMC: 11050102. DOI: 10.3390/ijms25084533.

Modulation of CD8 T Cell Responses by Radiotherapy-Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors.

Jeon S, Song C, Eom K, Kim I, Kim J Int J Mol Sci. 2023; 24(23).

PMID: 38069014 PMC: 10706388. DOI: 10.3390/ijms242316691.

References

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S . Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018; 198(6):777-787. DOI: 10.1164/rccm.201708-1707OC. View

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J . Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30):4833-9. DOI: 10.1200/JCO.2006.07.5937. View

Roach M, Robinson C, DeWees T, Ganachaud J, Przybysz D, Drzymala R . Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial. J Thorac Oncol. 2018; 13(11):1727-1732. DOI: 10.1016/j.jtho.2018.07.017. View

Min B . Spontaneous T Cell Proliferation: A Physiologic Process to Create and Maintain Homeostatic Balance and Diversity of the Immune System. Front Immunol. 2018; 9:547. PMC: 5868360. DOI: 10.3389/fimmu.2018.00547. View

Navarro-Martin A, Galiana I, Berenguer Frances M, Cacicedo J, Canas Cortes R, Comas Anton S . Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis. Int J Mol Sci. 2018; 19(12). PMC: 6320787. DOI: 10.3390/ijms19123963. View

McLaughlin M, Alam M, Smith L, Ryckman J, Lin C, Baine M . Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer. PLoS One. 2020; 15(11):e0241505. PMC: 7703900. DOI: 10.1371/journal.pone.0241505. View

Vanpouille-Box C, Alard A, Aryankalayil M, Sarfraz Y, Diamond J, Schneider R . DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017; 8:15618. PMC: 5472757. DOI: 10.1038/ncomms15618. View

Pauken K, Wherry E . Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015; 36(4):265-76. PMC: 4393798. DOI: 10.1016/j.it.2015.02.008. View

Dewan M, Galloway A, Kawashima N, Dewyngaert J, Babb J, Formenti S . Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15(17):5379-88. PMC: 2746048. DOI: 10.1158/1078-0432.CCR-09-0265. View

10.

Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U . Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2013; 190(1):26-33. PMC: 3889283. DOI: 10.1007/s00066-013-0450-y. View

11.

Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S . T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545(7652):60-65. PMC: 5554367. DOI: 10.1038/nature22079. View

12.

Popp I, Grosu A, Niedermann G, Duda D . Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol. 2016; 120(2):185-94. DOI: 10.1016/j.radonc.2016.07.013. View

13.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

14.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

15.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

16.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

17.

Bezjak A, Paulus R, Gaspar L, Timmerman R, Straube W, Ryan W . Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019; 37(15):1316-1325. PMC: 6524984. DOI: 10.1200/JCO.18.00622. View

18.

Nestle U, Adebahr S, Kaier K, Gkika E, Schimek-Jasch T, Hechtner M . Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiother Oncol. 2020; 148:82-88. DOI: 10.1016/j.radonc.2020.03.018. View

19.

Wild A, Herman J, Dholakia A, Moningi S, Lu Y, Rosati L . Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2016; 94(3):571-9. PMC: 4847529. DOI: 10.1016/j.ijrobp.2015.11.026. View

20.

Spurr L, Martinez C, Kang W, Chen M, Zha Y, Hseu R . Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022; 3(12):1498-1512. DOI: 10.1038/s43018-022-00467-x. View